Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure

NCT01210157 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 373

Last updated 2010-09-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether galectin-3 binding protein plasma levels can predict adverse cardiovascular events in patients with coronary artery disease and/or heart failure.

Conditions

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Christian A Gleissner, MD · Heidelberg University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-09-30
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01210157 on ClinicalTrials.gov